BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025
BridgeBio Pharma (Nasdaq: BBIO) announced its upcoming presentations at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The company will present additional open-label extension data from the ATTRibute-CM study through one oral presentation and two ePosters.
The presentations include data on cardiovascular mortality reduction at Month 42, NT-proBNP improvements at Month 30, and beneficial effects on NAC ATTR Stage changes. Key presenters include experts from Stanford University, UChicago Medicine, and University College London's Centre for Amyloidosis.
BridgeBio Pharma (Nasdaq: BBIO) ha annunciato le prossime presentazioni al Congresso 2025 della European Society of Cardiology (ESC) a Madrid, Spagna. La società presenterà dati aggiuntivi dall'estensione in aperto dello studio ATTRibute-CM con una presentazione orale e due ePoster.
Le presentazioni includeranno dati sulla riduzione della mortalità cardiovascolare al Mese 42, sui miglioramenti di NT-proBNP al Mese 30 e sugli effetti positivi sui cambiamenti dello stadio NAC ATTR. I relatori chiave provengono da Stanford University, UChicago Medicine e dal Centre for Amyloidosis dell'University College London.
BridgeBio Pharma (Nasdaq: BBIO) anunció sus próximas presentaciones en el Congreso 2025 de la European Society of Cardiology (ESC) en Madrid, España. La compañía presentará datos adicionales de la extensión abierta del estudio ATTRibute-CM mediante una presentación oral y dos ePosters.
Las presentaciones incluyen datos sobre la reducción de la mortalidad cardiovascular en el Mes 42, mejoras en NT-proBNP en el Mes 30 y efectos beneficiosos en los cambios de estadio NAC ATTR. Los ponentes principales son expertos de Stanford University, UChicago Medicine y del Centre for Amyloidosis de University College London.
BridgeBio Pharma (나스닥: BBIO)가 스페인 마드리드에서 열리는 유럽심장학회(ESC) 2025 연례학술대회에서 발표할 예정임을 발표했습니다. 회사는 ATTRibute-CM 연구의 공개연장(open-label extension) 추가 데이터를 한 편의 구두 발표와 두 건의 e포스터로 발표합니다.
발표 내용에는 42개월 시점의 심혈관 사망률 감소, 30개월 시점의 NT-proBNP 개선 및 NAC ATTR 병기 변화에 미치는 유익한 효과에 대한 데이터가 포함됩니다. 주요 발표자는 스탠퍼드 대학교, 시카고 대학교 의료원(UChicago Medicine), 유니버시티 칼리지 런던(University College London) 아밀로이드증 센터(Centre for Amyloidosis)의 전문가들입니다.
BridgeBio Pharma (Nasdaq : BBIO) a annoncé ses prochaines présentations au Congrès 2025 de la European Society of Cardiology (ESC) à Madrid, Espagne. La société présentera des données supplémentaires de l'extension en ouvert de l'étude ATTRibute-CM lors d'une présentation orale et de deux ePosters.
Les présentations comprennent des données sur la réduction de la mortalité cardiovasculaire au mois 42, des améliorations du NT-proBNP au mois 30 et des effets bénéfiques sur les changements de stade NAC ATTR. Les intervenants principaux sont des experts de la Stanford University, de UChicago Medicine et du Centre for Amyloidosis de l'University College London.
BridgeBio Pharma (Nasdaq: BBIO) kündigte seine bevorstehenden Präsentationen auf dem ESC-Kongress 2025 (European Society of Cardiology) in Madrid, Spanien, an. Das Unternehmen wird zusätzliche Open-Label-Extension-Daten der ATTRibute-CM-Studie in einer mündlichen Präsentation und zwei ePostern vorstellen.
Die Vorträge umfassen Daten zur Reduktion der kardiovaskulären Mortalität nach 42 Monaten, Verbesserungen des NT-proBNP nach 30 Monaten sowie positive Effekte auf Veränderungen des NAC-ATTR-Stadiums. Zu den Hauptreferenten gehören Experten der Stanford University, des UChicago Medicine und des Centre for Amyloidosis des University College London.
- None.
- None.
PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire oral presentation on additional open-label extension data from ATTRibute-CM and two ePosters with ATTRibute-CM data at Month 30 will be shared at the European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain from August 29 - September 1, 2025.
Oral Presentation
Acoramidis Reduces Cardiovascular Mortality (CVM): Results at Month 42 from the ATTRibute-CM Open-label Extension (OLE) Study
Presenter: Kevin Alexander, M.D., Stanford University School of Medicine, USA
Date: Saturday, August 30 at 1:15 pm CEST/7:15 am ET
ePosters:
Acoramidis-mediated Improvement in NT-proBNP at Month 30 Compared with Placebo in Patients with ATTR-CM: Results from the ATTRibute-CM Study
Presenter: Nitasha Sarswat, M.D. of UChicago Medicine, USA
Date: Sunday, August 31 at 4:15 pm CEST/10:15 am ET
Acoramidis Has a Beneficial Effect Compared with Placebo on Change from Baseline in NAC ATTR Stage at Month 30 in Patients with ATTR-CM: Results from the ATTRibute-CM Study
Presenter: Julian Gillmore, M.D., Ph.D., University College London's Centre for Amyloidosis, UK
Date: Saturday, August 29 at 3:15 pm CEST/9:15 am ET
About Attruby™ (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (
About BridgeBio
BridgeBio Pharma (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, and YouTube.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com
FAQ
When and where will BridgeBio (BBIO) present at ESC Congress 2025?
What data will BridgeBio (BBIO) present at ESC Congress 2025?
Who are the key presenters for BridgeBio's (BBIO) ESC Congress 2025 presentations?
What is the format of BridgeBio's (BBIO) presentations at ESC Congress 2025?
